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Abstract 
Intravascular Large B-cell lymphoma (IVLB-
CL)  is  an  exceptionally  rare  form  of  non-
Hodgkin  lymphoma  (NHL)  distinguished  by
the  preferential  growth  of  neoplastic  cells
within  blood  vessel  lumen.  Challenging  to
detect and deemed disseminated at diagnosis,
this  condition  is  characterized  by  a  highly
aggressive, inconspicuous course with a high
mortality rate. We describe the case of a 48
year-old  African-American  female  presenting
with a two month history of low-grade fevers
and malaise. Laboratory data was notable for
anemia, thrombocytopenia, elevated liver func-
tion tests, and hematuria. An extensive work-
up  for  infectious,  rheumatologic  and  malig-
nant causes was negative. Her symptoms pro-
gressed and within two weeks, she was admit-
ted for disseminated intravascular coagulation
(DIC). Her course was complicated by diffuse
pulmonary  hemorrhage  and  ultimately,  care
was  withdrawn.  Autopsy  identified  wide-
spread CD-20 positive intravascular large B-
cell lymphoma with significant hepatosplenic
involvement, characteristic of the Asian vari-
ant  IVLBCL.  This  case  uniquely  highlights
development of the Asian variant IVLBVL in a
previously undescribed race. Identified by its
intraluminal vascular growth pattern, IVLBCL
generally  spares  lymphatic  channels.
Diagnosis and differentiation of this condition
from  other  hematological  malignancies  via
skin,  visceral  and  bone  marrow  biopsy  is
imperative  as  anthracycline-containing
chemotherapies  may  significantly  improve
clinical  outcomes.  This  article  outlines  the
common  presentation,  natural  course,  and
treatment options of IVLBCL, along with the
histopathology,  immunohistochemistry,  and
chromosomal aberrations common to this con-
dition.
Case Report
In  June  of  2008,  a  48  year-old  African-
American  woman  presented  to  her  primary
care physician describing a three week history
of  low-grade  fevers  and  malaise.  Antibiotics
were  administered,  with  no  resolution  of
symptoms. She was subsequently admitted for
further work-up. On admission, her laboratory
data was notable for anemia and thrombocy-
topenia.  Initial  testing  included  a  bron-
cheoalveolar lavage (BAL) and lumbar punc-
ture, which were non-diagnostic. A liver biopsy
was notable for a mononuclear infiltrate con-
sistent with chronic hepatitis. Laboratory data
was notable for a normal Coombs test, autoim-
mune and vasculitic panel, and hepatitis panel.
Computed tomography of the chest, abdomen
and pelvis (CT-CAP) was unremarkable. She
was discharged one month later with no formal
diagnosis. 
Within two weeks, she was re-admitted for
progression of symptoms. Admission laborato-
ry data was notable for severe anemia (Hgb 6.0
g/dL), leukopenia (2.5 g/dL); thrombocytopenia
(10ﾥ109), and an elevated lactate dehydroge-
nase (LDH; 1900 U/L; reference range 122-222
U/L).  Aspartate  transaminase  (AST;  77  U/L),
alanine aminotransferase (ALT; 46 U/L), total
bilirubin (8.8 mg/dL) and direct bilirubin (6.2
mg/dL)  were  all  noted  to  be  elevated.
Haptoglobin was low. Prothrombin time (PT),
activated partial thromboplastin time (APTT)
and d-dimer levels were elevated. A peripheral
blood smear showed schistocytes and polychro-
masia. Findings were deemed consistent with
microangiopathic hemolytic anemia and dis-
seminated  intravascular  coagulation  (DIC).
She  was  treated  with  plasma  exchange  and
high dose steroid administration (methylpred-
nisolone 125 mg/day) without effect. An exten-
sive  work-up  for  viral,  bacterial  and  fungal
pathogens was again, non-revealing. Magnetic
resonance cholangiopancreatography (MRCP)
of the liver showed hepato  splenomegaly with
intra-organ  hemosiderin  deposition.  Repeat
CT-CAP defined diffuse hazy opacities in both
lungs, hepato  splenomegaly and mild thicken-
ing of the walls of the cecum and ascending
colon (Figure 1). On repeat CT of the chest
three days later, there was interval increase in
the  bilateral  nodular  opacities,  air  bron-
chograms,  subcutaneous  anasarca  and  find-
ings consistent with pulmonary edema (Figure
2).  Bronchoalveolar  lavage  (BAL)  identified
diffuse pulmonary hemorrhages. On hospital-
day 5, the patient rapidly developed acute res-
piratory distress syndrome (ARDS) and pulse-
less electrical activity (PEA). Despite success-
ful resuscitation, she remained unresponsive
and care was ultimately withdrawn. 
Bone marrow biopsy results performed ear-
lier  that  week  were  available  following  her
demise. Samples showed evidence of hyercel-
lular  (80-90%  cellular)  with  trilineage
hematopoiesis and a subtle atypical mononu-
clear cell infiltrate composed of large cells with
slightly irregular nuclear contours and multi-
ple visible nucleoli. An autopsy identified dif-
fuse alveolar hemorrhage, bilateral renal con-
gestion  with  acute  tubular  necrosis  (ATN),
hepatomegaly and a single enlarged perisplenic
lymph node. Histological examination of multi-
ple organs confirmed diffuse intravascular large
B-cell type lymphoma (IVLBCL).
Histologic andimmunohistochemical
findings
Histological  examination  showed  capillary
wall  congestion  with  large;  atypical  lympho-
cytes  (Figure  3).  On  higher  magnification,
lymphocytes displayed vesicular nuclei, promi-
nent  nucleoli  and  frequent  mitotic  figures
(Figure 4). Some cells showed coarse nuclear
chromatin  or  irregular  and  indented  nuclei
(Figure 4). Staining with common leukocyte
antigen  and  B  cell  marker  CD-20  exhibited
strong uptake by neoplastic cells (Figure 5). 
Discussion
First characterized by Pfleger and Tappeiner
in 1959,1 IVLBCL has emerged as an elusive
malignancy characterized by a covert presenta-
tion and highly aggressive course. It is defined
by the World Health Organization (WHO) as a
rare and highly aggressive lymphoma variant,
identified by the proliferation of large tumor
cells  within  the  lumen  of  small  to  medium-
sized vessels.2 We present the first reported
case of the Asian variant IVLBCL in an African-
American individual and proceed to review its
unique  presentation,  progression  and
response to treatment.
Since its first description more than half-a-
century ago, literature on IVLBCL has contin-
ued to accumulate. Until recently, the relative
paucity  of  cases  has  limited  epidemiologic
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research. However, it is currently recognized
as a disease primarily of the elderly, with a
median age in the sixth decade of life and a
male-to-female ratio exceeding 3:1.3 The wide
variability  in  IVLBCL’s  clinical  presentation
makes detection challenging with the majority
of  patients  present  late  within  the  disease
process.  Despite  variability  in  presentation,
specific patterns have been successfully traced
to a surprising common entity: the geographic
distribution of patients. Appropriately reflect-
ing their origins, two main subtypes IVLBCL
are recognized: the western variant and the
Asian variant.
The western or classical variant remains the
most  common  sub-type  identified  in  North
America and Europe. It is characterized by a
prominence  of  neurologic  and  dermatologic
findings,  both  at  initial  presentation  and
throughout  its  course.  Neurologic  symptoms
may include alterations in consciousness and
peripheral  neuropathy.  Cutaneous  features
may manifest as telangiectasias, diffuse ery-
thematous streaks, purpuric macules and nod-
ules.4 The  cutaneous  variant of  the  western
variant class is a unique subtype which is less
aggressive  than  all  other  forms  of  IVLBCL,
most  commonly  affecting  pre-menopausal
females. 
The Asian or hemophagocytic variant, like
it’s counterpart, has a title reminiscent of its
origin and is characterized by anemia (66%),
thrombocytopenia  (58%),  hemophagocytosis
(61%), bone marrow involvement (75%), res-
piratory symptoms (34%), B-symptoms (fever,
night-sweats; 76%), hypoalbuminaemia (<30
g/L; 61%) and hepatosplenomegaly.5,6 In con-
trast  to  the  Western  variant,  neurological
symptoms (27%) and cutaneous lesions (15%)
are rare and, when present, suggest an alter-
native diagnosis.5 High lactate dehydrogenase
(LDH;  98%)  and  disseminated  intravascular
coagulation  (DIC;  25%)  are  common  fea-
tures.3,6 Most Asian variant IVLBCL cases have
been reported in Southwestern Japan. A few
case reports have described the hemophago-
cytic variant within the Western hemisphere.
However, the majority of these have involved
either immigrants from eastern countries or a
known  family  history  of  Asian  descent.  Our
case uniquely describes an African-American
within  the  western  hemisphere,  presenting
with the Asian variant.
Theories regarding the source of this the
observed geographical difference remain dis-
puted. More recent conjectures have included
potential ethnic differences involved in inflam-
matory marker production such as sIL2R which
appears markedly increased in Asian variant
patients, in comparison to western variants.3
Other theories speculate towards an environ-
mental component given that the majority of
Asian variant cases have been documented in
Southwestern Japan where human T-cell lym-
photropic virus type-1 (HTLV-1) is prominent.
Helminthic infectious may also represent an
environmental  trigger.  In  contrast  to  other
hemophagocytic-associated  lymphomas,
Epstein-Barr virus (EBV) has been reported in
only a few IVLBCL cases and is not thought be
causative. 
The genetic alterations in IVLBCL remain
under  investigation.  Aberrations  in  chromo-
somes 1, 6, 18, 11 and 13 have all been postu-
lated as sources.3,7-11 However, in a retrospec-
tive  analysis  of  cytogenetic  abnormalities,
Shimada et al. identified that only 57% of 84
patients displayed cytogenetic abnormalities.3
Determination  of  the  progenitor  cell  lines
remains an area of intense investigation. Most
cells express CD 19, CD20, and CD79a, consis-
tent with B-cell origin. In addition to B cells,
both  intravascular  T  cell  and  natural  killer
(NK)  cell  lines  have  been  identified  and
should not be considered a variant of IVLBCL.12
It is plausible that Asian variant IVLBCL repre-
sents a unique variant of the germinal center
B cell-like (GCB) form of CD5+ Diffuse Large B
Cell Lymphoma (DLBCL).5,13 Accordingly, CD5–
lines may be indicative of the western variant.
The  paucity  of  extravascular  migration
remains  IVLBCL’s  most  perplexing  feature.
Defective interactions between luminal walls
and  lymphoma  cells  may  play  a  role.14 In
healthy individuals, lymphocytes bind to high
endothelial venules (HEV) on vessel walls via
the  lymphocyte  homing  receptor,  thereby
allowing transverse movement across the walls
into peripheral regions. Western variant IVLB-
CL,  in  particular,  appears  to  congregate  in
regions with low HEV, such as the brain and
skin.14 HEV  deficiency  within  vessel  lumens
may  thus  prevent  extravasation  into  the
periphery. Other possibilities include deficien-
Case Report
Figure  1.  Chest  computed  tomography:
Admission  CT  displaying  diffuse  hazy
opacities in both lung fields with occasion-
al nodular formation.
Figure  2.  Chest  computed  tomography:
Day 3 CT displaying interval increase in
bilateral  nodular  opacities,  air  bron-
chograms and pulmonary edema.
Figure  3.  Capillary  wall  congestion  with
large  atypical  lymphocytes  and  diffuse
hemorrhage. Hematoxylin and eosin stain,
intermediate magnification.
Figure 4. Lymphocytes displaying vesicular
nuclei,  prominent  nucleoli  and  frequent
mitotic figures. Coarse nuclear chromatin
and  indented  nuclei  noted  as  well.
Hematoxylin and eosin stain, intermediate
magnification.[page 28] [Rare Tumors 2012; 4:e10]
cies in essential transvascular migration mol-
ecules  such  as  CD29  (b1-Integrin),  CD54
(intracellular adhesion molecule 1), and CD18
(Integrin b2) superficially expressed by lym-
phoma cells.15,16In the Asian variant, the mech-
anism  of  hemophagocytosis  remains  poorly
understood,  but  may  be  influenced  by
macrophage colony stimulating factor and IL-
6.9 It  is  possible  that  hemophagocytosis  is
linked to cellular extravasation as studies have
shown that the presence of hemophagocytosis
correlates with disease dissemination (along
with B-symptoms and elevated levels of soluble
IL-2 receptor).5 Notably, although the majority
of IVLBC cases involve small vessels, at least
seven case reports have identified IVLBCL in
large  vessels.17 The  mechanism  of  this  is
unknown.
As  stated  previously,  IVLBCL  may  present
with  wide  clinical  variability.  Characteristic
physical exam findings associated with lym-
phoma, such as lymphadenopahthy or tumor
burden,  are  often  absent  thus  requiring
greater reliance on laboratory data. Suspicion
should  be  raised  in  patients  describing
headaches, skin abnormalities, hepatospleno  -
megaly,  or  constitutional  complaints.  Initial
laboratory  tests  should  include  a  complete
blood  count,  serum  LDH,  b-2  microglobulin,
monoclonal serum protein, a complete hepatic
and renal panel and thyroid function studies.
Cytogenetic studies should also be considered.
The gold standard of diagnosis remains organ
biopsy. Diffuse spread of the disease allows for
physician discretion in determining the biopsy
site.  For  Asian  IVLBCL,  bone  marrow  (BM)
biopsy  offers  the  most  reliable  results  as
intrasinusoidal tumor involvement is frequent-
ly encountered (up to 96%).6,9 Serial BM biop-
sies have been shown to enhance diagnostic
accuracy.18 Despite infrequent cutaneous fea-
tures, Asian-variant IVLBCL is commonly iso-
lated from skin biopsies and if positive, may
prove  a  simple  and  useful  diagnostic  proce-
dure.6Transbronchial biopsy may be performed
if pulmonary symptoms are present. Hepatic
and splenic biopsies are useful in the setting
of  hepatosplenomegaly  and  show  sinusoidal
involvement in up to 89% of patients.9
Tumor cells are large with scant basophilic
or amphophilic cytoplasm and moderately dis-
persed  chromatin.  Frequent  mitotic  figures
and prominent vesicular nucleoli are common.
Cells are rarely detected in peripheral blood.
Sinusoidal distribution often occurs within the
bone marrow, liver and spleen. As mentioned,
erythrocyte-hemophagocytic cells are detected
in the vast majority of BM biopsies. However,
in the appropriate clinical context, the pres-
ence of classic findings including thrombocy-
topenia, fever and hepatosplenomegaly may be
considered diagnostic even in the absence of
hemophagocytosis.  Computed  tomography
(CT)  scans  are  rarely  diagnostic.  However,
reports  regarding  the  use  of  18-
Fluorodeoxyglucose-Positron  Emission
Tomography (FDG-PET) have been promising
with characteristic uptake in the bone marrow
and involved organs.19,20 The overall prognosis
for  most  IVLBCL  cases  remains  poor.
Historically,  most  patients  have  been  diag-
nosed with stage IV disease, or post-mortem.
Post-mortum diagnosis appears less common
in Asian variants (36%) versus the Western
variants  (64%).5 Prognostic  comparisons
between the Western and Asian variants are
similar, as are responses to treatment.5 The
rarity  of  IVLBCL  has  made  randomized  con-
trolled trial assessment difficult. Historically,
combination  chemotherapy,  typically  CHOP,
has been utilized with dismal results. However,
the addition of Rituximab, a monoclonal anti-
body to CD-20, has led to substantial improve-
ments  in  recovery,  nearly  doubling  survival
length.21 European studies have determined an
81%  survival  rate  at  3  years  with  combined
immunochemotherapy,22versus just 33% in the
absence  of  rituximab.23 To  date,  no  studies
have  evaluated  the  addition  of  Rituximab
specifically  in  the  Asian  variant  IVLBCL.
Autologous stem cell support (ASCT) has been
evaluated in a number of small studies and
shown efficacy, primarily in individuals under-
going  their  first  remission.3,23 However,  the
advanced age of most patients excludes them
from  this  option.  Allogenic  peripheral  blood
stem  cell  transplant  has  been  utilized  with
variable  results  in  the  setting  of  failed
chemotherapy.24 With treatment, Asian variant
IVLBCL survival times range 12.5 months to
22.5 months.21,25 Cases exclusive to the skin
appear to have a better response rate (3-year
survival 56%).26 Median survival with anthra-
cycline therapy is estimated to be 13 months.5
Etoposide has been effective in the setting of
hemophagocytic syndrome.27
Conclusions
Despite more than 50 years of research, IVL-
BCL remains a highly elusive malignancy typi-
fied by limited treatment options and a gaurd-
ed prognosis. We describe the first recorded
occurrence  of  Asian  variant  IVLBCL  in  an
African-American  within  the  western  hemi-
sphere. This case is of particular interest as
descriptions  of  the  Asian  variant  IVLBCL  in
non-Asian populations is limited. No obvious
mechanism has yet surfaced explaining this
unique phenomenon. However, environmental
factors characteristic to certain topographies
may  play  a  lesser  role  than  once  previously
considered.  Alternatively,  African  and  Asian
races may share particular genomic sequences
predisposing  them  to  the  Asian  variant.
Regardless of the cause, it remains imperative
that continued research be promoted to better
understand this unique malignancy.
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